MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

I-BET151

CAS No. : 1300031-49-5

MCE 站：I-BET151

产品活性：I-BET151 是一种 BET溴结构域 (BET bromodomain) 抑制剂，抑制 BRD4，BRD2 和 BRD3 的 pIC₅₀ 分别为 6.1，6.3 和 6.6。

研究领域：Epigenetics

作用靶点：Epigenetic Reader Domain

In Vitro: I-BET151 (GSK1210151A) causes a significant dose- and time-dependent decrease in the proportion of myeloma cells in S/G₂ phase at 24, 48, and 72 hours. The most pronounced effect is observed at 72 hours in all 6 myeloma cell lines, starting at 100 nM. Dual Ki67/propidium iodide staining confirmed that the majority of live cells resided in the G₀ phase after treatment with I-BET151 at 1 μM for 72 hours commensurate with a dose- and time-dependent decrease in cell proliferation and abrogation of bromodeoxyuridine incorporation.

In Vivo: I-BET151 (GSK1210151A) demonstrates low blood clearance in the rat (~20% liver blood flow) and good oral systemic exposure which resulted in good oral bioavailability. High clearance is observed in the dog (~95% liver blood flow). The systemic exposure in the dog is low, resulting in a poor oral bioavailability of 16%. The high blood clearance in dog correlates well with the high intrinsic clearance observed in dog microsomes and hepatocytes, whereas the low intrinsic clearances seen in rat and mouse (mouse IVC 1.6 mL/min/g; CLb 8 mL/min/kg) correlate with lower in vivo blood clearances in these species. Due to the low systemic exposure observed in the dog, I-BET151 is investigated in the mini-pig as a potential second species for toxicological evaluation where it showed low clearance (~32% liver blood flow) and good bioavailability (65%). In an in vivo model of subcutaneous myeloma, I-BET151 (50 mg/kg)-treated mice has four- to five fold smaller myeloma tumors (P<0.001) and a significantly reduced rate of tumor size doubling than vehicle-treated mice (P<0.001).

相关产品：Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Reprogramming Compound Library  |  Anti-Blood Cancer Compound Library  |  A-485  |  Curcumin  |  Birabresib  |  C646  |  JQ-1 (carboxylic acid)  |  Anacardic Acid  |  SGC-CBP30  |  MG 149  |  KG-501  |  A-366  |  NSC 228155  |  CPI-203  |  PFI-1  |  IACS-9571 hydrochloride  |  ACBI1  |  GSK2801  |  MI-3  |  (+)-JQ1 PA  |  SGC-iMLLT  |  PF-CBP1 hydrochloride  |  Bromosporine  |  EML 425  |  MS436  |  GSK1379725A  |  GSK6853  |  HJB97  |  MS31 trihydrochloride  |  MS645  |  PROTAC BRD9 Degrader-1  |  BAZ2-ICR

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。